Rapid Reviews in Oncology®: Practice-Changing Data in DLBCL, A Rapid Update from Frankfurt

Release Date: July 14, 2020
Expiration Date: July 14, 2021

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in diffuse large B-cell lymphoma (DLBCL). The Rapid Reviews in Oncology^® legacy format is designed to quickly update physicians on data presented at the European Hematology Association (EHA) Annual Meeting in June 2020. The faculty discuss groundbreaking data for transplant-ineligible patients with relapsed/refractory (R/R) DLBCL, including antibodies targeting novel cell-surface antigens, inhibitors of B-cell receptor signaling, and cellular immunotherapy. The expert panel highlight the implications and applications of these data in everyday clinical practice, with a focus on optimizing outcomes and personalizing care for patients with DLBCL.

This educational activity is an archive of the live virtual symposium held on June 22, 2020.

Acknowledgement of Support

This educational activity is supported by an educational grant from MorphoSys US Inc.

Target Audience

This educational activity is directed toward medical oncologists and hematologists involved in the treatment and management of patients with DLBCL. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of DLBCL may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Review current strategies for the management of DLBCL in the relapsed settings
• Explain ongoing studies and recent clinical trial findings from trials evaluating novel approaches for the management of DLBCL
• Place recent evidence in the context of clinical gaps in the field, evolving treatment paradigms, and recent approvals for the care of patients with DLBCL

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Elizabeth Budde, MD, PhD
Assistant Professor
Department of Hematology & Hematopoietic Cell Transplantation
City of Hope
Duarte, CA

Disclosures: Grant Research Support: Astrazeneca, Amgen, Merck; Consultant: Roche, Kite Pharma.

Kieron Dunleavy, MD
Professor of Medicine
Director of the Lymphoma Program
Co-director of the Microbial Oncology Program
Division of Hematology & Oncology
George Washington University Cancer Center
Washington, DC

Disclosures: Consultant: Pharmacyclics, Karyopharm.

Gilles A. Salles, MD, PhD
University Professor
Head of Hematology
Claude Bernard University of Lyon
Hospices Civils de Lyon
Lyon, France

Disclosures: Consultant: Autolus, Celgene, Genmab, Gilead, Janssen, MorphoSys, Novartis, Roche.

Andrew D. Zelenetz, MD, PhD
Medical Director, Quality Informatics
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: MEI Pharma, Roche, Gilead, Beigene; Consultant: Genentech/Roche, Gilead, Celgene, Janssen, Amgen, Novartis, Adaptive Biotech, MorphoSys, AbbVie; Other: Beigene- DMC Chair.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.